TrialArthritis & rheumatology (Hoboken, N.J.)2025

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.

Rohit Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.